找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Approaching China‘s Pharmaceutical Market; A Fundamental Guide Ming Q. Lu Book 2015 Springer International Publishing Switzerland 2015 CFD

[復制鏈接]
樓主: Diverticulum
11#
發(fā)表于 2025-3-23 10:32:06 | 只看該作者
Erfolgreiche Strategiearbeit im Mittelstand of the articles that are most relevant to overseas pharmaceutical companies, and the major regulations related to drug registration, quality management, and inspection. The corresponding guidances are listed and will be discussed in the corresponding independent chapters.
12#
發(fā)表于 2025-3-23 16:39:43 | 只看該作者
Erfolgreiche Strategien für E-Commerceese State Council in 2008. In this chapter, we’ll briefly introduce the basic knowledge of the Chinese IPR system, the key regulatory policies, and the differences between China and western countries. We hope this section for Pharmaceutical Patent Protection may help overseas and multinational pharm
13#
發(fā)表于 2025-3-23 18:34:51 | 只看該作者
Unternehmensführung & Controllingt ones for multinational pharmaceutical companies and pharmacy school students to understand. We hope this chapter may help the readers get a basic idea of China’s regulatory environment through the understanding of the CFDA structure and function and its differences from its counterparts in the wes
14#
發(fā)表于 2025-3-24 02:05:48 | 只看該作者
15#
發(fā)表于 2025-3-24 03:00:36 | 只看該作者
16#
發(fā)表于 2025-3-24 06:41:18 | 只看該作者
https://doi.org/10.1007/978-3-8350-9511-3ous clinical phases have to follow the CFDA’s defined requirements; the investigator’s responsibilities and safety reporting requirements are very unique from those of the western world; all the clinical sites and investigators have to be certified by the CFDA to conduct the clinical trials; all eth
17#
發(fā)表于 2025-3-24 11:51:23 | 只看該作者
Ergebnisse der empirischen Untersuchung,ug registration in China, IMCT data shall be in line with the requirements of the CFDA regulations. In this section, we’ll introduce the development strategies with a focus on IMCT, its subtypes, the corresponding advantages and disadvantages of each potential pathway, the application processes, the
18#
發(fā)表于 2025-3-24 16:28:25 | 只看該作者
19#
發(fā)表于 2025-3-24 20:15:26 | 只看該作者
20#
發(fā)表于 2025-3-25 02:29:51 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2025-10-13 02:52
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
临沭县| 平武县| 太仓市| 成武县| 荆州市| 蒲江县| 磐安县| 修文县| 勐海县| 新兴县| 安多县| 叶城县| 晋中市| 黄大仙区| 阿瓦提县| 黄平县| 长沙县| 灵宝市| 溆浦县| 乌拉特前旗| 宜宾市| 衡阳市| 天气| 渭南市| 曲周县| 景泰县| 项城市| 顺平县| 芜湖县| 施甸县| 读书| 丰镇市| 潮安县| 乐亭县| 藁城市| 北安市| 浙江省| 越西县| 汉中市| 蒙山县| 阿鲁科尔沁旗|